After meeting with meetings with Heska (HSKA) management, Benchmark analyst Raymond Myers came away with a better understanding of how current investments are likely to accelerate future cash flows and how its new products and international expansion can accelerate revenue growth in 2019. He also said Zoetis' (ZTS) deal to acquire Abaxis (ABAX) "puts a high price tag on Heska," estimating that valuing Heska on the same terms as Abaxis would imply a valuation of $143 per Heska share. Myers raised his price target on Heska to $120 from $100 and keeps a Buy rating on the shares.

Barclays lowered the firm's price target on Zoetis to $230 from $260 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst expects the Q1 reports to provide continuing evidence of improvement in generics and biosimilars for the specialty pharmaceuticals group.